NCT00157573View on ClinicalTrials.gov

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

April 30, 2010

Conditions
Ovarian CancerFallopian Tube Cancer
Interventions
DRUG

GM-CSF, sargramostim

GM-CSF subcutaneous injection

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Bayer

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00157573 - GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter